Natco Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve Un-audited Financial Results for ....

6th August 2026 Corporate Relationship Department Manager – Listing M/s. BSE Limited M/s. National Stock Exchange of India Ltd Mumbai 400 001. Mumbai 400 051. Scrip Code: 524816 Scrip Code: NATCOPHARM Dear Sir/Madam, Sub: Notice of Board Meeting under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 This is to inform you that the meeting of the Board of Directors of the Company is scheduled to be held on Friday, the 14th day of August 2026 to consider among other things, the following items of business and related matters: Sl. Item of Business 1 To consider the Unaudited Financial Results for the quarter ended 30th June 2026 2 To consider interim dividend, if any, for the financial Year ending 2026-27 Please further note that pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time-to-time TRADING WINDOW for dealing in the securities of the Company by the Employee(s), connected persons and their immediate relatives will be closed from 7th August 2026 to 16th August 2026 (both days inclusive). Trading window will be re-opened on 17th August 2026. Thanking you, Yours faithfully, For NATCO Pharma Limited Chekuri Venkat Ramesh Company Secretary & Compliance Officer